Skip to main content
. 2007 Aug 17;44(12):763–771. doi: 10.1136/jmg.2007.050450

Table 3 Frequencies of clinical abnormalities according to the gene mutated (BRAF, KRAS, or MEK) and according to the clinical diagnosis (CFC or CS with RAS‐pathway mutations).

Characteristic BRAF KRAS MEK CFC Kavamura index7 CS with BRAF, MEK or KRAS mutation CS with HRAS mutation10
Patients, n 22 7 15 23 54 14 37
Median age, years 4.7 8.7 7.7 5 6 9
Age at clinical diagnosis 1 2 1.7 1 1.6
Median age of mother, years 32 31 31 31 33
Median age of father, years 33 35 32 32 36
Antenatal
 Birth weight >90th centile 9/18 (50) 3/6 (50) 5/13 (38) 9/19 (47) 6/12 (50)
 Polyhydramnios 11/20 (55) 3/7 (43) 10/15 (67) 12/22 (54) 9/13 (69)
 Nuchal lucency 4/19 (21) 2/6 (33) 1/7 (14) 14/19 (21) 2/10 (20)
 Caesarean 5/20 (25) 3/5 (60) 2/12 (17) 3/18 (17) 5/12 (42)
 Hypoglycaemia 2/17 (12) 0/6 (0) 0/9 (0) 1/19 (5) 1/10 (10) 9%
 Hypotonic 16/19 (84) 6/6 (100) 7/10 (70) 13/19 (68) 28% 13/13 (100)
 Failure to thrive 19/20 (95) 6/7 (86) 10/14 (71) 17/21 (81) 14/14 (100) 100%
 Postnatal growth retardation 14/19 (74) 5/7 (71) 9/13 (69) 13/20 (65) 12/14 (86)
 Splenomegaly 2/18 (11) 2/7 (29) 2/13 (15) 4/21 (19) 15% 1/11 (9)
 Hepatomegaly 4/20 (20) 3/6 (50) 2/13 (15) 6/21 (29) 9% 2/12 (17)
Growth
 Short stature, <−2SD 13/21 (62) 7/7 (100) 11/15 (73) 13/23 (56) 78% 12/13 (92)
 Median stature, SD −2.3 −3.2 −2 −2 −2.8
Heart
 Pulmonic valve stenosis 11/22 (50) 3/7 (43) 3/14 (21) 6/22 (27) 7/14 (50)
 Atrial septal defect 5/22 (23) 2/7 (29) 3/14 (21) 6/22 (27) 3/14 (21)
 Hypertrophic cardiomyopathy 9/22 (41) 3/7 (43) 3/14 (21) 9/22 (41) 4/14 (29) 51%
 Arrhythmia 0/20 (0) 0/7 (0) 0/14 (0) 0/21 (0) 0/13 (0) 31%
 Total heart defect 19/22 (86) 7/7 (100) 6/14 (43) 17/22 (77) 78% 9/14 (64) 63%*
Oncology
 Leukaemia 0/22 (0) 0/6 (0) 0/12 (0) 0/21 (0) 0/12 (0)
 Solid tumour 0/22 (0) 0/6 (0) 0/12 (0) 0/21 (0) 0/12 (0) 13.5%
Dysmorphism
 Relative macrocephaly 17/22 (77) 7/7 (100) 11/15 (73) 14/23 (61) 78% 14/14 (100) 91%
 Microcephaly 0/22 (0) 0/7 (0) 1/15 (7) 1/23 (4) 0/13 (0)
 Triangular facies 8/22 (36) 3/7 (43) 3/13 (23) 7/21 (33) 4/14 (29)
 Hypertelorism 20/22 (91) 7/7 (100) 11/15 (73) 21/23 (91) 46% 11/14 (79)
 Downslanting palpebral fissures 13/22 (59) 6/7 (86) 9/14 (64) 14/22 (64) 61% 8/14 (57)
 Ptosis 9/19 (47) 6/7 (86) 8/13 (61) 12/19 (63) 52% 7/13 (54)
 Epicanthal folds 10/19 (53) 5/5 (100) 6/12 (50) 12/20 (60) 59% 5/11 (45)
 Posteriorly angulated ears 19/22 (86) 5/7 (71) 12/14 (86) 20/22 (91) 76% 12/14 (86)
 Thick ears 19/22 (86) 5/7 (71) 9/12 (75) 19/21 (90) 30% 10/13 (77)
 Large earlobes 17/22 (77) 2/5 (40) 10/12 (83) 17/20 (85) 10/13 (77)
 Low‐set ears 17/21 (81) 6/7 (86) 13/15 (87) 20/22 (91) 10/14 (71)
 Anteverted nostrils 10/22 (45) 3/5 (60) 8/12 (67) 12/22 (55) 6/12 (50)
 High cranial vault 16/21 (76) 4/6 (67) 10/13 (77) 18/21 (86) 7/12 (58)
 Bitemporal constriction 13/22 (59) 3/5 (60) 7/11 (64) 16/20 (80) 81% 5/13 (38)
 Large mouth 9/22 (41) 1/6 (17) 4/13 (31) 6/21 (29) 8/13 (61)
 Thick lips 9/22 (41) 2/7 (29) 7/13 (54) 10/21 (48) 8/14 (57)
 Micrognathia 4/19 (21) 2/7 (29) 4/11 (36) 5/18 (28) 24% 2/12 (17)
 Prominent philtrum 10/29 (50) 3/7 (43) 9/12 (75) 13/20 (65) 6/12 (50)
 Short neck 20/22 (91) 6/7 (86) 11/12 (92) 20/21 (95) 50% 11/13 (85)
 Webbed neck 13/20 (65) 6/7 (86) 6/11 (54) 13/20 (65) 41% 8/12 (67)
 Pterygium colli 6/22 (27) 3/7 (43) 3/12 (25) 14/20 (70) 4/13 (31)
 Coarse face 14/21 (67) 4/7 (57) 9/12 (75) 14/20 (70) 12/14 (86)
 Low posterior hairline 7/20 (35) 2/5 (40) 5/9 (55) 8/17 (47) 4/12 (33)
Malformations
 Hyperextensible fingers 10/19 (53) 4/6 (67) 8/11 (73) 10/17 (59) 13% 10/14 (71) 100%
 Pectus excavatum/carinatum 10/16 (63) 4/6 (67) 11/14 (79) 11/17 (65) 9/12 (75)
Skin characteristics
 Curly hairs 19/22 (86) 2/7 (29) 13/15 (87) 21/23 (91) 72% 11/14 (79)
 Sparse hairs 21/22 (95) 5/7 (71) 7/13 (54) 20/21 (95) 85% 10/14 (71)
 Sparse or absent eyebrows 17/22 (77) 4/7 (57) 12/14 (86) 18/23 (78) 63% 12/13 (92)
 Sparse or absent eyelashes 12/21 (57) 3/7 (43) 9/13 (69) 14/21 (67) 67% 9/13 (69)
 Palmoplantar hyperkeratosis 4/21 (19) 0/7 (0) 3/14 (21) 5/21 (24) 13% 2/14 (14)
 General hyperkeratosis 3/20 (15) 1/6 (17) 0/11 (0) 3/20 (15) 37% 1/13 (8)
 Eczema 1/19 (5) 0/6 (0) 2/10 (20) 1/19 (5) 2/13 (15)
 Deep palmar/plantar creases 15/21 (71) 2/5 (40) 7/10 (70) 12/19 (63) 11/14 (79)
 Hyperpigmentation 2/18 (11) 1/6 (17) 4/11 (36) 5/20 (25) 6% 2/11 (18)
 Hyperelastic skin 13/20 (65) 2/6 (33) 6/11 (54) 10/21 (48) 22% 9/13 (69)
 Dry skin 10/19 (53) 1/6 (17) 4/10 (40) 6/19 (32) 7/12 (58)
 Excess skin hands/foot 9/20 (45) 2/6 (33) 5/11 (36) 6/19 (32) 9% 9/14 (64) 100%
 Ichytosis 1/18 (6) 1/6 (17) 1/10 (10) 2/20 (10) 31% 1/11 (9)
 Café‐au‐lait patches 4/20 (20) 1/6 (17) 2/13 (15) 3/20 (15) 9% 2/13 (15)
 Naevi >10 4/21 (19) 0/7 (0) 2/14 (14) 4/22 (18) 1/13 (8)
 Lentigines >100 3/22 (14) 0/7 (0) 1/14 (7) 1/22 (4) 2/14 (14)
 Papillomata 0/20 (0) 0/6 (0) 0/10 (0) 0/19 (0) 0/13 (0) 39%
 Haemangioma 5/20 (25) 2/6 (33) 1/10 (10) 4/19 (21) 24% 3/13 (23)
Neurological
 Motor delay 21/21 (100) 7/7 (100) 13/14 (93) 21/21 (100) 14/14 (100)
 Age of walk (median) 2.5 2.7 2.0 2.1 3.0
 Speech delay 20/21 (95) 7/7 (100) 11/13 (85) 19/20 (95) 46% 14/14 (100)
 First words (median) 3.0 2.3 3.0 2.9
 Mental retardation 21/21 (100) 6/7 (86) 11/13 (85) 21/21 (100) 91% 14/14 (100)
 Autistic features 3/15 (20) 2/6 (33) 5/8 (62) 3/14 (21) 5/11 (45)
 Seizures 3/18 (17) 0/6 (0) 4/13 (31) 3/19 (16) 15% 4/12 (33) 11%
 Nystagmus 4/18 (22) 3/6 (50) 4/7 (57) 5/17 (29) 30% 4/11 (36)
Neurosensory
 Strabismus 9/20 (45) 3/5 (60) 6/12 (50) 8/19 (42) 33% 8/12 (67)
 Myopia 5/13 (38) 1/4 (25) 3/9 (33) 5/11 (45) 3/10 (30)
 Deafness 3/12 (25) 0/3 (0) 2/12 (17) 1/13 (8) 3/8 (38)

CFC, cardio‐facio‐cutaneous syndrome; CS, Costello syndrome.

*Without hypertrophic cardiomyopathy.

All data are number affected/total number (%) unless otherwise indicated.

Kavamura index,7 and HRAS‐positive patients with CS patients reported by Kerr et al10 are also indicated for comparison.